Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis

Name: Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
Published: 2026
License: Public Domain

Immunomic Therapeutics, Inc. · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

allergen immunotherapy, japanese red cedar (jrc) pollinosis, japanese cedar pollen (jcp) allergy, seasonal allergic rhinitis, self-amplifying rna (sarna), interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis

Related documents